Shows / Community Health Media
Community Health Media
Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars •…
Episodes
Community Health MediaNavigating CLL From Frontline to Relapse with Drs. Joanna Rhodes, Prioty Islam & Nicole Lamanna
What shapes treatment decisions in chronic lymphocytic leukemia (CLL), from frontline therapy through relapse? Dr. Joanna Rhodes, Dr. Prioty Islam, and Dr…
Community Health MediaHER2-Low & Ultralow Breast Cancer: Testing & T-DXd with Drs. Neil Iyengar & Sunil Badve
Why does accurate HER2 testing matter more than ever for patients with breast cancer? Dr. Neil Iyengar and Dr. Sunil Badve discuss the evolving understanding…
Community Health MediaSpecial CHM Conversation: Second-Line ER+/HER2- mBC with Drs. Seth Wander & Paolo Tarantino
How is the rapidly changing treatment landscape reshaping second-line ER-positive, HER2-negative metastatic breast cancer care? In this Special CHM…
Community Health MediaESR1-Mutated Breast Cancer: Oral SERDs and Vepdegestrant with Drs. Jason Mouabbi & Erika Hamilton
How should clinicians navigate the growing number of treatment options for ESR1-mutated metastatic breast cancer? Dr. Jason Mouabbi and Dr. Erika Hamilton…
Community Health MediaT-DXd Across HER2+ Breast Cancer with Drs. Paolo Tarantino & Seth Wander
How is T-DXd reshaping the treatment pathway for HER2-positive breast cancer? Drs. Paolo Tarantino and Seth Wander discuss the rapidly evolving role of…
Community Health MediaT-DXd in HER2+ Breast Cancer with Drs. Ruta Rao & Irene Kang
How is T-DXd changing the treatment landscape for HER2-positive breast cancer? Drs. Ruta Rao and Irene Kang discuss the evolving role of trastuzumab deruxtecan…
Community Health MediaT-DXd Plus Pertuzumab in First-Line HER2+ Breast Cancer with Drs. Jason Mouabbi & Neil Iyengar
How is DESTINY-Breast09 changing the first-line treatment landscape for metastatic HER2-positive breast cancer? Drs. Jason Mouabbi and Neil Iyengar discuss the…
Community Health MediaNavigating First-Line CLL Treatment with Drs. Kerry Rogers, William Wierda & Catherine Coombs
With more targeted therapies available for CLL, how are clinicians navigating the growing number of first-line treatment options? Drs. Kerry Rogers, William…
Community Health MediaEvolving First-Line HER2+ Metastatic Breast Cancer with Drs. Sonya Reid & Shruti Singh
For more than a decade, THP—established by the landmark CLEOPATRA trial— defined the first-line standard for HER2-positive metastatic breast cancer. Now…
Community Health MediaThis Moment in Medicine: First-Line ADCs in Metastatic TNBC with Dr. Senthil Damodaran
Are antibody-drug conjugates becoming the new first-line standard for metastatic triple-negative breast cancer? At This Moment in Medicine, hosted by Community…
Community Health MediaThis Moment In Medicine: First-Line HER2+ Metastatic Breast Cancer with Dr. Mothaffar Rimawi
How should we approach first-line treatment as the HER2-positive metastatic breast cancer landscape rapidly evolves? At This Moment in Medicine, hosted by…
Community Health MediaThis Moment in Medicine: T-DXd in Early HER2+ BC with Dr. Michelina Cairo
Where should T-DXd fit in the treatment of high-risk, early-stage HER2-positive breast cancer? At This Moment in Medicine, hosted by Community Health Media…
Community Health MediaThis Moment in Medicine: Rethinking Adjuvant Therapy in ER+ Breast Cancer with Dr. Akshjot Puri
How is adjuvant treatment for ER-positive, HER2-negative breast cancer changing? At This Moment in Medicine, Dr. Akshjot Puri examines key data from OPTIMA…
Community Health MediaDrs. Jason Mouabbi, Ruta Rao, & Mark Pegram - Unpacking DESTINY-Breast09 in HER2+ mBC
A new era in HER2-positive metastatic breast cancer is here.Dr. Jason Mouabbi, Dr. Ruta Rao, and Dr. Mark Pegram break down the groundbreaking DESTINY-Breast09…
Community Health MediaDr. Anne O'Dea & Dr. Mabel Mardones - SERENA-6 & ctDNA-Guided Therapy in mBC
Can we improve outcomes by changing treatment before radiographic progression occurs? In this in-depth discussion, Dr. Anne O'Dea and Dr. Mabel Mardones…
Community Health MediaDr. Rena Callahan & Dr. Aditya Bardia - Integrating T-DXd in HER2+ Breast Cancer: DB11, DB05 & DB09
HER2-positive breast cancer treatment is evolving rapidly. With FDA approvals from DESTINY-Breast11 and DESTINY-Breast05, when should clinicians incorporate…
Community Health MediaDr. Neil Iyengar, Dr. Joyce O'Shaughnessy, & Dr. Ana Garrido-Castro - Evolving ADCs in 1L mTNBC
The first-line treatment landscape for metastatic triple-negative breast cancer is changing rapidly. Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, and Dr. Ana…
Community Health MediaMATTERHORN Roundtable: Perioperative FLOT & Immunotherapy Updates in Gastric Cancer
The treatment landscape for perioperative gastric cancer is changing rapidly. In this expert roundtable, leading GI oncology specialists discuss the…
Community Health MediaEMERALD-3 Roundtable: Hepatocellular Carcinoma Trial Breakdown & Insights
Could EMERALD-3 redefine the treatment paradigm for unresectable hepatocellular carcinoma? In this special roundtable discussion recorded at ASCO 2026, Dr…
Community Health MediaDr. Ursa Brown Glaberman & Dr. Karthik Giridhar- Managing Capiva-sertib & the AKT Path-way in 2L mBC
How are we navigating the evolving landscape of second-line treatment for metastatic HR-positive, HER2-negative breast cancer? In this full-length discussion…
Community Health MediaDr. Sarah Premji, Dr. Reshma Mahtani & Dr. Eleftherios Mamounas - Expanding T-DXd Across HER2 + Breast Cancer
How is trastuzumab deruxtecan (T-DXd) reshaping treatment across early-stage and metastatic HER2-positive breast cancer? Dr. Sarah Premji, Dr. Reshma Mahtani…
Community Health MediaDr. Jason Mouabbi, Dr. Fenting Yan, & Dr. Paolo Tarantino - First-Line T-DXd in HER2+ mBC
Can T-DXd plus pertuzumab finally replace the CLEOPATRA regimen as the new first-line standard for metastatic HER2-positive breast cancer? In this…
Community Health MediaDr. Abi Siva & Dr. Carey Anders - DESTINY-Breast05, DESTINY- Breast11 and T-DXd Integration
How is T-DXd reshaping treatment for patients with early-stage HER2-positive breast cancer Dr. Abi Siva and Dr. Carey Anders discuss the evolving role of T-DXd…
Community Health MediaDr. Megan Kruse, Dr. Ryan Rader, & Dr. Praveen Vikas - DB11 & DB05 Change HER2+ Care
Metastatic triple-negative breast cancer has long been one of the most challenging breast cancer subtypes to treat. But with the emergence of ADCs, the…
Community Health MediaDr. Megan Kruse, Dr. William Gradishar, & Dr. Ajaz Khan - Integrating T-DXd Across HER2+ Care
How should clinicians integrate T-DXd across the entire HER2-positive breast cancer treatment continuum? Dr. Megan Kruse, Dr. William Gradishar, and Dr. Ajaz…
Community Health MediaDr. Mark Pegram & Dr. Seth Wander - Endocrine Resistance & ESR1 Mutations
How should clinicians approach endocrine resistance in ER-positive metastatic breast cancer? Dr. Mark Pegram and Dr. Seth Wander explore the evolving science…
Community Health MediaDr. Jason Mouabbi, Dr. Alison Conlin & Dr. Reva Basho - Frontline TNBC and ADC Advances
TNBC has long been one of the most difficult breast cancer subtypes to treat. But with ADCs reshaping the treatment landscape, are we finally entering a new…
Community Health MediaDr. Gregory Vidal, Dr. Pooja Advani, & Dr. Tari King - T-DXd in Early HER2+ Breast Cancer
How will DESTINY-Breast11 and DESTINY-Breast05 change the treatment of early-stage HER2-positive breast cancer? Dr. Gregory Vidal, Dr. Pooja Advani, and Dr…
Community Health MediaDr. Hope Rugo, Dr. Sarah Hurvitz, & Dr. Jennifer Tseng - T-DXd: New Curative Approvals & HER2+ Landscape
Three new approvals for trastuzumab deruxtecan (T-DXd) are reshaping the treatment landscape for HER2-positive breast cancer. Dr. Hope Rugo, Dr. Sarah Hurvitz…
Community Health MediaDr. Nusayba Bagegni & Dr. Philip Lammers - Targeting & Sequencing Endocrine Pathways After CDK4/6i
What is the optimal treatment strategy after progression on a CDK4/6 inhibitor in HR-positive, HER2-negative metastatic breast cancer? Dr. Nusayba Bagegni and…
Community Health MediaDr. Sangeetha Reddy & Dr. Ahmed Elkhanany - First-Line ADCs IN Metastatic Triple-Negative Breast Cancer
What should replace chemotherapy in the first-line treatment of immunotherapy-ineligible metastatic triple-negative breast cancer(TNBC)? Dr. Sangeetha Reddy…
Community Health MediaDr. Mabel Mardones & Dr. Joyce O'Shaughnessy - T-DXd in Early HER2+ Breast Cancer
The treatment for early-stage HER2-positive breast cancer has entered a new era. Dr. Mabel Mardones and Dr. Joyce O'Shaughnessy discuss how they are…
Community Health MediaDr. Joyce O'Shaughnessy, Dr. Anthony Lucci, & Dr. Mothaffar Rimawi - DB11 & DB05 Change HER2+ Care
The treatment landscape for early-stage HER2-positive breast cancer is evolving rapidly. In this discussion, Dr. Joyce O'Shaughnessy, Dr. Anthony Lucci, and…
Community Health MediaDr. Marcela Mazo Canola, Dr. Akshjot Puri, & Dr. Giancarlo Moscol - AKT-Pathway Sequencing in ER+ mBC
How do we navigate the increasingly complex second-line landscape for HR+/HER2- metastatic breast cancer? Dr. Marcela Mazo Canola, Dr. Akshjot Puri, and Dr…
Community Health MediaDr. Caitlin Taylor & Dr. Andrew Davis - Can Camizestrant Change HR+ Breast Cancer Care?
A new approach to treating endocrine resistance may be emerging in metastatic HR-positive breast cancer with the SERENA-6 trial. Dr. Caitlin Taylor and Dr…
Community Health MediaDr. Komal Jhaveri, Dr. Shanu Modi, & Dr. Sarah Tolaney - Early Stage HER2+ Breast Cancer: DB11 & DB05
The treatment landscape for early-stage HER2-positive breast cancer has shifted. Dr. Komal Jhaveri, Dr. Sarah Tolaney, and Dr. Shanu Modi discuss the landmark…
Community Health MediaDr. Megan Kruse & Dr. Lukas Delasos - ADC Integration & Toxicity in Breast and Thoracic Oncology
As the ADC landscape expands, how is datopotamab deruxtecan redefining the treatment paradigm for both breast and lung cancer? In this episode of CHM…
Community Health MediaDr. Rao & Dr. Nasrazadani – The Second-Line Landscape for HR+/HER2- mBC: The Role of Capivasertib
The second-line landscape for HR+/HER2- metastatic breast cancer is shifting rapidly with the detection of truncal mutations. In this episode of CHM…
Community Health MediaDr. Hope Rugo & Dr. Rebecca Shatsky - Dato-DXd & First-Line ADC Strategies in Metastatic TNBC
How is Dato-DXd redefining first-line mTNBC? In this episode of CHM Conversations, Dr. Hope Rugo and Dr. Rebecca Shatsky discuss the TROPION-Breast02 trial…
Community Health MediaDr. Hope Rugo & Dr. Rebecca Shatsky - Earlier ESR1 Detection & Oral SERDs in Metastatic Breast Cancer
Can earlier ESR1 mutation detection help delay progression and preserve quality of life? In this episode of CHM Conversations, Dr. Hope Rugo and Dr. Rebecca…
Community Health MediaDr. Neil Iyengar & Dr. Ticiana Leal - ADC Integration in Breast & Lung Cancer: The Role of Dato-DXd
How are clinicians navigating the complex balance between immunotherapy and antibody-drug conjugates? In this episode of CHM Conversations, Dr. Neil Iyengar…
Community Health MediaDr. Iyengar, Dr. Bhave & Dr. Mahtani – ESR1 Monitoring & Camizestrant in Metastatic Breast Cancer
Can molecular monitoring help clinicians intervene earlier to extend the benefit of first-line therapy? In this episode of CHM Conversations, Dr. Neil Iyengar…
Community Health MediaDr. Megan Kruse & Dr. Carol Tweed – ESR1 Mutation Monitoring & Oral SERDs in Metastatic Breast Cancer
Are we moving past the traditional "wait for progression" model in HR+ mBC? In this episode of CHM Conversations, Dr. Megan Kruse and Dr. Carol Tweed examine…
Community Health MediaDr. Jason Mouabbi & Dr. Ahmed Elkhanany - SERENA-6, ESR1 Mutations & Molecular Progression
What if we could change treatment before scans show progression? In this episode of CHM Conversations, Dr. Jason Mouabbi and Dr. Ahmed Elkhanany explore the…
Community Health MediaDr. Rebecca Shatsky & Dr. Reva Basho - Sequencing PI3K/AKT Therapies in Metastatic Breast Cancer
How are clinicians navigating the growing number of targeted therapy options in HR-positive, HER2-negative metastatic breast cancer? In this CHM Conversations…
Community Health MediaDrs. Neil Iyengar, Manali Bhave & Reshma Mahtani - Navigating AKT Inhibition Efficacy & Tolerability
How are clinicians optimizing the use of AKT inhibitors in HR-positive metastatic breast cancer? In this CHM Conversations episode, Drs. Neil Iyengar, Manali…
Community Health MediaDr. Erica Mayer & Dr. Seth Wander - Biomarker Testing & Precision Targeting in the PI3K Pathway
How is molecular profiling reshaping HR+ metastatic breast cancer treatment? In this episode of CHM Conversations, Dr. Erica Mayer and Dr. Seth Wander navigate…
Community Health MediaDr. Seth Wander & Dr. Erica Mayer - SERENA-6 and Camizestrant in Breast Cancer
Can early intervention change the course of metastatic HR+ breast cancer? In this expert discussion, Dr. Seth Wander and Dr. Erica Mayer break down the…
Community Health MediaDrs. Alvarez, Dr. Mazo-Canola & Dr. Sandoval-Leon - The Future of Breast Cancer Treatment & Precision Oncology
In this special Spanish-language episode, experts Dr. Ricardo Alvarez, Dr. Marcela Mazo-Canola, and Dr. Ana Sandoval-Leon sit down to discuss the breakthroughs…
Community Health MediaDr. Jason Mouabbi & Dr. Eric Singhi - ADCs in Breast & Lung Cancer
What happens when breast and thoracic oncology collide over the future of ADCs? In this cross-specialty conversation, Dr. Jason Mouabbi and Dr. Eric Singhi…
Community Health MediaDr. Sigrun Hallmeyer & Dr. William Gradishar - SERENA-6 & Early Endocrine Resistance
What if we could detect endocrine resistance before it shows up on scans? In this CHM Conversations episode, Dr. Sigrun Hallmeyer and Dr. William Gradishar…
Community Health MediaDr. VK Gadi & Dr. Tarah Ballinger - DB09, PATINA, DB05 & DB11 in HER2+ Breast Cancer
The HER2-positive landscape is undergoing its most significant shift in over a decade! In this in-depth CHM Conversations episode, VK Gadi and Tarah Ballinger…
Community Health MediaDr. Ruta Rao & Dr. VK Gadi - Can T-DXd Change Early HER2+ Breast Cancer Forever?
In this expert discussion, Dr. VK Gadi and Dr. Ruta Rao break down the data that’s reshaping treatment for HER2-positive breast cancer — from DESTINY-Breast 05…
Community Health MediaDr. Irene Kang & Dr. Aditya Bardia - First-Line HER2+ Metastatic Breast Cancer: DESTINY-Breast09 & the Future of Care
Recorded live, this in-depth conversation features Dr. Irene Kang and Dr. Aditya Bardia breaking down the DESTINY-Breast09 data and what it means for…
Community Health MediaDr. Neil Iyengar & Dr. Komal Jhaveri - Early-Stage HER2+ Breast Cancer: DESTINY-Breast11, DESTINY-Breast05 & What Comes Next
Recorded with Drs. Neil Iyengar and Komal Jhaveri, this in-depth discussion breaks down the most practice-shifting data in early-stage HER2-positive breast…
Community Health MediaDr. Gregory Vidal & Dr. Nusayba Bagegni - Is HER2+ Metastatic Breast Cancer Curable? DESTINY-Breast09, Patina & What Comes Next
Recorded live with Drs. Gregory Vidal and Nusayba Bagegni, this in-depth conversation tackles one of the most provocative questions in HER2-positive metastatic…
Community Health MediaDr. Alison Conlin & Dr. Heather McArthur - DB-11 & DB-05: Rewriting Neoadjuvant & Adjuvant HER2+ Breast Cancer Strategy
Recorded live, this in-depth conversation features Dr. Alison Conlin and Dr. Heather McArthur as they break down the evolving role of antibody–drug conjugates…
Community Health MediaDrs. Bill Gradishar, Tarah Ballinger, & Megan Kruse - HER2+ Metastatic Breast Cancer: Cleopatra, DESTINY-Breast09 & What Comes Next
For more than a decade, the Cleopatra regimen transformed outcomes in HER2-positive metastatic breast cancer — delivering landmark overall survival gains and…
Community Health MediaDr. Mark Pegram & Dr. Carol Tweed - Is Cleopatra Finally Over? New First-Line Strategies in HER2+ Metastatic Breast Cancer
Recorded live around the latest data from SABCS, ASCO, and ESMO, this in-depth conversation features Dr. Mark Pegram and Dr. Carol Tweed examining whether the…
Community Health MediaDrs. Neil Iyengar, Komal Jhaveri, & Igor Makhlin - HER2+ Metastatic Breast Cancer: Is T-DXd + Pertuzumab the New First-Line Standard?
For more than a decade, CLEOPATRA defined first-line therapy in HER2-positive metastatic breast cancer. Now, DESTINY-Breast09 is forcing a fundamental rethink…